Want to see KR:214390 full AI Analyst Report?
Top Page
Kyongbo Pharmaceutical Co., Ltd.
(214390)
Select Model
Select Model
Rating:49Neutral
Price Target:
₩5,164.00
Action:N/A
Date:10/28/26
The score is held back primarily by weak cash generation (persistently negative free cash flow) and rising leverage, despite improving revenue and gross margin trends. Technicals also point to a bearish setup with negative momentum and price below key moving averages. Valuation is neutral-to-slightly unfavorable given a mid-20s P/E alongside thin and volatile profitability and a modest dividend yield.
Positive Factors
Revenue Growth
Steady revenue expansion indicates improving demand and/or pricing across the company’s pharmaceutical portfolio. If maintained, this broader top-line base can support operating leverage, strengthen commercial scale, and provide a foundation for more durable earnings improvement over coming quarters.
Negative Factors
Persistent Negative Free Cash Flow
Repeatedly negative free cash flow means operating cash has not covered investment and working-capital demands, limiting self-funded growth. The widening TTM deficit increases the company’s need for financing or balance-sheet support and could constrain investment if the pattern persists.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Steady revenue expansion indicates improving demand and/or pricing across the company’s pharmaceutical portfolio. If maintained, this broader top-line base can support operating leverage, strengthen commercial scale, and provide a foundation for more durable earnings improvement over coming quarters.
Read all positive factors
Kyongbo Pharmaceutical Co., Ltd. (214390) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩122.88B
Dividend Yield0.97%
Average Volume (3M)15.32K
Price to Earnings (P/E)24.7
Beta (1Y)0.06
Revenue Growth10.51%
EPS Growth-51.40%
CountryKR
Employees505
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding23,906,860
10 Day Avg. Volume15,991
30 Day Avg. Volume15,316
Financial Highlights & Ratios
PEG Ratio-7.87
Price to Book (P/B)0.95
Price to Sales (P/S)0.52
P/FCF Ratio-4.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kyongbo Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1987 and based in Asan, South Korea, Kyongbo Pharmaceutical Co., Ltd is a key player in the South Korean pharmaceutical market, primarily focusing on the production and distribution of active pharmaceutical ingredients (APIs). Its A...
Kyongbo Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
61
Positive
Balance Sheet
55
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 279.55B | 264.10B | 238.56B | 216.36B | 196.26B | 170.66B |
| Gross Profit | 104.11B | 97.82B | 82.42B | 63.08B | 44.42B | 33.13B |
| EBITDA | 16.74B | 16.72B | 21.60B | 17.24B | 12.99B | 4.21B |
| Net Income | 4.97B | 182.29M | 4.64B | 2.97B | 610.59M | -7.50B |
Balance Sheet | ||||||
| Total Assets | 367.57B | 319.24B | 283.89B | 266.31B | 240.54B | 236.98B |
| Cash, Cash Equivalents and Short-Term Investments | 13.83B | 8.05B | 6.13B | 5.35B | 7.22B | 4.29B |
| Total Debt | 158.00B | 126.67B | 91.43B | 75.94B | 64.51B | 56.59B |
| Total Liabilities | 220.58B | 173.80B | 137.73B | 121.92B | 96.84B | 91.28B |
| Stockholders Equity | 146.99B | 145.44B | 146.15B | 144.38B | 143.70B | 145.70B |
Cash Flow | ||||||
| Free Cash Flow | -43.98B | -34.08B | -13.03B | -6.03B | -3.06B | -355.61M |
| Operating Cash Flow | 11.95B | 7.46B | 149.12M | 4.84B | 10.13B | 17.97B |
| Investing Cash Flow | -50.66B | -37.98B | -14.63B | -14.27B | -14.88B | -16.17B |
| Financing Cash Flow | 43.07B | 33.76B | 13.87B | 7.16B | 6.59B | -9.22B |
Kyongbo Pharmaceutical Co., Ltd. Technical Analysis
Negative
―
Price Trends
5330.40
Negative
5263.80
Negative
5788.45
Negative
Market Momentum
-56.71
Positive
37.72
Neutral
29.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:214390, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 5299.00, equal to the 50-day MA of 5330.40, and equal to the 200-day MA of 5788.45, indicating a bearish trend. The MACD of -56.71 indicates Positive momentum. The RSI at 37.72 is Neutral, neither overbought nor oversold. The STOCH value of 29.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:214390.
Kyongbo Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | ₩139.61B | 8.21 | ― | 3.22% | 7.46% | -14.42% | |
58 Neutral | ₩141.36B | 7.82 | ― | 4.80% | 6.59% | 185.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ₩125.32B | 7.07 | ― | 0.30% | -17.85% | 81.91% | |
49 Neutral | ₩122.88B | 24.71 | ― | 0.97% | 10.51% | -51.40% | |
47 Neutral | ₩164.86B | -4.34 | ― | 0.96% | -4.54% | -88.02% | |
44 Neutral | ₩113.23B | -0.83 | ― | ― | -2.43% | -234.71% |
* General Sector Average
KR:214390
Kyongbo Pharmaceutical Co., Ltd.
5,140.00
-709.14
-12.12%
KR:000020
Dong Wha Pharm Co., Ltd.
5,100.00
-1,090.56
-17.62%
KR:000520
Samil Pharmaceutical Co., Ltd.
7,650.00
-1,850.00
-19.47%
KR:001360
SAMSUNG PHARMACEUTICAL.CO.,Ltd.
1,203.00
-330.00
-21.53%
KR:271980
Jeil Pharmaceutical Co. Ltd.
8,600.00
-5,780.00
-40.19%
KR:293480
Hana Pharm Co., Ltd.
8,070.00
-3,186.39
-28.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.